A different gut microbiome linked to inflammation found in cirrhotic patients with and without hepatocellular carcinoma

Annals of Hepatology

Volumn 18, Issue 3, 2019, Pages 480-487

  Piñero, Federico ^a,b   Vazquez, Martín ^c   Baré, Patricia ^d   Rohr, Cristian ^c   Mendizabal, Manuel ^a,b   Sciara, Mariela ^c   Alonso, Cristina ^a,b   Fay, Fabián ^c   Silva, Marcelo ^a,b  

^a UNIVERSIDAD AUSTRAL   (Argentina)

^b Educational and Awareness Network   (Argentina)

^c Rosario   (Argentina)

^d Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

Inflammatory pathways; Liver cancer; Microbiota

Indexed keywords

INTERLEUKIN 6; TUMOR NECROSIS FACTOR; CYTOKINE; RNA 16S;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AMPLICON; ARTICLE; CHILD PUGH SCORE; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYSIPELOTRICHACEAE; FECES ANALYSIS; FEMALE; FIRMICUTES; FOLLOW UP; FUSOBACTERIUM; HUMAN; INFLAMMATION; INTESTINE FLORA; LACHNOSPIRACEAE; LEUCONOSTOCACEAE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MICROBIAL DIVERSITY; MODEL FOR END STAGE LIVER DISEASE SCORE; NONHUMAN; OBSERVATIONAL STUDY; PORTAL HYPERTENSION; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; TAXONOMY; CASE CONTROL STUDY; COMPLICATION; FECES; LIVER TUMOR; METABOLISM; MICROBIOLOGY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; X-RAY COMPUTED TOMOGRAPHY; DISEASE SEVERITY; GENDER; GROUPS BY AGE; HEPATITIS; PREVOTELLA;

CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CYTOKINES; FECES; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL MICROBIOME; HUMANS; INFLAMMATION; LIVER CIRRHOSIS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 85066919194     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.aohep.2018.10.003     Document Type: Article

References (29)

1. Chen, Y., Yang, F., Lu, H., Wang, B., Chen, Y., Lei, D., et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology 54 (2011), 562–572.
2. Bajaj, J.S., Heuman, D.M., Hylemon, P.B., Sanyal, A.J., White, M.B., Monteith, P., et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol 60 (2014), 940–947.
3. Qin, N., Yang, F., Li, A., Prifti, E., Chen, Y., Shao, L., et al. Alterations of the human gut microbiome in liver cirrhosis. Nature 513 (2014), 59–64.
4. Grąt, M., Hołówko, W., Gałecka, M., Grąt, K., Szachtaz, P., Lewandowsk, Z., et al. Gut microbiota in cirrhotic liver transplant candidates. Hepatogastroenterology 61 (2014), 1661–1667.
5. Chen, Y., Guo, J., Qian, G., Fang, D., Shi, D., Guo, L., et al. Gut dysbiosis in acute-on-chronic liver failure and its predictive value for mortality. J Gastroenterol Hepatol 30 (2015), 1429–1437.
6. D'Amico, G., The clinical course of cirrhosis. Population based studies and the need of personalized medicine. J Hepatol 60 (2014), 241–242.
7. Sherman, M., Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis 30 (2010), 3–16.
8. Ripoll, C., Groszmann, R.J., Garcia-Tsao, G., Bosch, J., Grace, N., Burroughs, A., et al. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol 50 (2009), 923–928.
9. Dapito, D.H., Mencin, A., Gwak, G.Y., Pradere, J.P., Jang, M.K., Mederacke, I., et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 21 (2012), 504–516.
10. Zhang, H.L., Yu, L.X., Yang, W., Tang, L., Lin, Y., Wu, H., et al. Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats. J Hepatol 57 (2012), 803–812.
11. Darnaud, M., Faivre, J., Moniaux, N., Targeting gut flora to prevent progression of hepatocellular carcinoma. J Hepatol 58 (2013), 385–387.
12. von Elm, E., Altman, D.G., Egger, M., Pocock, S.J., Gøtzsche, P.C., Vandenbroucke, J.P., STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370 (2007), 1453–1457.
13. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 53 (2010), 397–417.
14. Trotti, A., Colevas, A.D., Setser, A., Rusch, V., Jaques, D., Budach, V., et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13 (2003), 176–181.
15. European Association for the Study of the Liver, EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 56 (2012), 908–943.
16. Carbonetto, B., Fabbro, M.C., Sciara, M., Seravalle, A., Méjico, G., Revale, S., et al. Human microbiota of the argentine population – a pilot study. Front Microbiol, 7, 2016, 51.
17. Xia, F., Chen, J., Fung, W.K., Li, H., A logistic normal multinomial regression model for microbiome compositional data analysis. Biometrics 69 (2013), 1053–1063.
18. Oksanen, J., Vegan: community ecology package. R package version 1. 2011, 17–18.
19. Mandal, S., Van Treuren, W., White, R.A., Eggesbø, M., Knight, R., Peddada, S.D., Analysis of composition of microbiomes: a novel method for studying microbial composition. Microb Ecol Health Dis, 26, 2015, 27663.
20. Shaw, P.J., Lamkanfi, M., Kanneganti, T.D., NOD-like receptor (NLR) signaling beyond the inflammasome. Eur J Immunol 40 (2010), 624–627.
21. Bajaj, J.S., Sterling, R.K., Betrapally, N.S., Nixon, D.E., Fuchs, M., Daita, K., et al. HCV eradication does not impact gut dysbiosis or systemic inflammation in cirrhotic patients. Aliment Pharmacol Ther 44 (2016), 638–643.
22. Flemer, B., Lynch, D.B., Brown, J.M., Jeffery, I.B., Ryan, F.J., Claesson, M.J., et al. Tumour-associated and non-tumour-associated microbiota in colorectal cancer. Gut 66 (2017), 633–643.
23. Morgan, X.C., Tickle, T.L., Sokol, H., Gevers, D., Devaney, K.L., Ward, D.V., et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol, 13, 2012, R79.
24. Zackular, J.P., Baxter, N.T., Iverson, K.D., Sadler, W.D., Petrosino, J.F., Chen, G.Y., et al. The gut microbiome modulates colon tumorigenesis. MBio, 4, 2013 e00692-e00613.
25. Simpson, H.L., Campbell, B.J., Review article: dietary fibre–microbiota interactions. Aliment Pharmacol Ther 42 (2015), 158–179.
26. Bultman, S.J., Jobin, C., Microbial-derived butyrate: an oncometabolite or tumor-suppressive metabolite?. Cell Host Microbe 16 (2014), 143–145.
27. Li, J., Sung, C.Y., Lee, N., Ni, Y., Pihlajamäki, J., Panagiotou, G., et al. Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice. Proc Natl Acad Sci USA 113 (2016), E1306–E1315.
28. Ponziani, F.R., Bhoori, S., Castelli, C., Putignani, L., Rivoltini, L., Del Cherico, F., et al. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease. Hepatology, 2018, 10.1002/hep.30036 [Epub ahead of print].
29. Grat, M., Wronka, K.M., Krasnodebski, M., Masior, T., Lewandowski, Z., Kosinska, I., et al. Profile of gut microbiota associated with the presence of hepatocellular cancer in patients with liver cirrhosis. Transplant Proc 48:5 (2016), 1687–1691.